Yanqiang Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Yanqiang Li has a total of 150 co-authors. Here are the top co-authors by number of shared publications:
- Kaifu Chen
Basic and Translational Research Division, Department of Cardiology, Boston Children’s Hospital, Boston, USA
8 shared publications - Qi Cao
Department of Urology, Feinberg School of Medicine, Northwestern University, Chicago, USA
6 shared publications - Lili Zhang
Departments of Cardiology (Y.Y., G.X., S.S., M.T., K.A., Y. Li, S.Y., M.C., Y. Liu, Jiehui Chen, Yunxia Wang, Yi Wang, R.Z., X.G., D.L., Jiayi Chen, S.P.S., W.T.P., K.C., L.Z.), Boston Children’s Hospital, Boston, MA
4 shared publications - John P. Cooke
Department of Cardiovascular Sciences, Houston Methodist Research Institute, 6670 Bertner Ave, Houston, TX 77030, USA
3 shared publications - Qingshu Meng
Department of Urology, Northwestern University Feinberg School of Medicine, Chicago, USA
3 shared publications - Xin Wang
The Kidney and Urinary Tract Center Abigail Wexner Research Institute at Nationwide Children's Columbus Ohio USA
3 shared publications
Latest Publications
- 25 August 2026
- Published by Wolters Kluwer Health in Circulation
- Vol. 154 (8) , 771-774
Spatial and Single-Nucleus Multiomics Profiling Reveals Heterogeneous Endothelial Cell Overabundance in Endocardial Fibroelastosis
- 25 August 2026
- Published by Wolters Kluwer Health in Circulation
- Vol. 154 (8) , 771-774
Spatial and Single-Nucleus Multiomics Profiling Reveals Heterogeneous Endothelial Cell Overabundance in Endocardial Fibroelastosis
- Top Cited PapersOpen Access
Nanopore direct RNA sequencing and the epitranscriptome: Advances in mapping native RNA landscapes
Nanopore direct RNA sequencing (DRS) has transformed transcriptomics by enabling single‐molecule, long‐read sequencing of native RNA without the need for reverse transcription or amplification. In contrast to short‐read RNA‐seq and cDNA‐based long‐read approaches, DRS can simultaneously capture multiple RNA modifications, full‐length transcript architecture, alternative splicing patterns, and poly(A) tail features within individual molecules, thereby providing an integrated view of transcriptomic and epitranscriptomic regulation. In this comprehensive review, we outline the biophysical principles underlying nanopore DRS and trace its technological evolution. We compare its performance with short‐read RNA sequencing, long‐read cDNA sequencing, and conventional RNA‐modification mapping strategies, highlighting its advantages in isoform‐resolved quantification and multilayer RNA feature integration, while also clarifying contexts in which alternative or combined approaches may be more appropriate for robust biological interpretation. We further summarize optimized experimental workflows, including library construction strategies tailored to diverse RNA biotypes (mRNA, rRNA, tRNA, circRNA, miRNA, and nonpoly(A) transcripts), as well as recommended quality‐control procedures and sequencing optimization practices. Emphasizing recent computational advances and translational applications of DRS, we cover state‐of‐the‐art algorithms for RNA modification detection, transcript reconstruction, and isoform quantification. We also propose analytical pipelines for poly(A) tail length inference and integrative frameworks that jointly analyze these regulatory layers. We distinguish direct nanopore signals from computational inferences to define confidence levels and emphasize benchmarking and orthogonal validation of readouts. Practical implementation examples are included to facilitate reproducible analysis. Finally, we highlight emerging applications of integrated DRS, including the resolution of complex transcriptomes, the characterization of coordinated epitranscriptomic regulation, and the identification of disease‐associated RNA signatures. We also discuss current technical challenges and future perspectives, particularly in relation to multi‐omics integration and the broader deployment of DRS in precision medicine as well as in plant and animal research.
Top Cited PapersOpen AccessNanopore direct RNA sequencing and the epitranscriptome: Advances in mapping native RNA landscapes
Nanopore direct RNA sequencing (DRS) has transformed transcriptomics by enabling single‐molecule, long‐read sequencing of native RNA without the need for reverse transcription or amplification. In contrast to short‐read RNA‐seq and cDNA‐based long‐read approaches, DRS can simultaneously capture multiple RNA modifications, full‐length transcript architecture, alternative splicing patterns, and poly(A) tail features within individual molecules, thereby providing an integrated view of transcriptomic and epitranscriptomic regulation. In this comprehensive review, we outline the biophysical principles underlying nanopore DRS and trace its technological evolution. We compare its performance with short‐read RNA sequencing, long‐read cDNA sequencing, and conventional RNA‐modification mapping strategies, highlighting its advantages in isoform‐resolved quantification and multilayer RNA feature integration, while also clarifying contexts in which alternative or combined approaches may be more appropriate for robust biological interpretation. We further summarize optimized experimental workflows, including library construction strategies tailored to diverse RNA biotypes (mRNA, rRNA, tRNA, circRNA, miRNA, and nonpoly(A) transcripts), as well as recommended quality‐control procedures and sequencing optimization practices. Emphasizing recent computational advances and translational applications of DRS, we cover state‐of‐the‐art algorithms for RNA modification detection, transcript reconstruction, and isoform quantification. We also propose analytical pipelines for poly(A) tail length inference and integrative frameworks that jointly analyze these regulatory layers. We distinguish direct nanopore signals from computational inferences to define confidence levels and emphasize benchmarking and orthogonal validation of readouts. Practical implementation examples are included to facilitate reproducible analysis. Finally, we highlight emerging applications of integrated DRS, including the resolution of complex transcriptomes, the characterization of coordinated epitranscriptomic regulation, and the identification of disease‐associated RNA signatures. We also discuss current technical challenges and future perspectives, particularly in relation to multi‐omics integration and the broader deployment of DRS in precision medicine as well as in plant and animal research.
- Open Access
- 26 March 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
A dual role of EZH2 in regulating A-to-I RNA editing and mRNA stability through ADAR
Adenosine-to-inosine (A-to-I) RNA editing, catalyzed by adenosine deaminases acting on RNA (ADARs), is a widespread modification in metazoans. Cumulative evidence has revealed the altered A-to-I editing profiles in cancers, but the underlying mechanism remains unclear. Here, we discover the well-known histone lysine methyltransferase enhancer of zeste homologue 2 (EZH2) as an unexplored ADAR interactor and editing regulator in prostate cancer (PCa). Through competing with interleukin enhancer binding factor 2 (ILF2) for ADAR1 binding, EZH2 reshapes the substrate selectivity of ADAR1 and thus exhibits a bidirectional role in editing regulation. Moreover, EZH2 depletion induces the translational repression of transportin-1 (TRN1), which further results in the accumulation of cytoplasmic ADAR1p110 isoform to protect many oncogenic transcripts from degradation. Consistently, depletion of ADAR1 dramatically enhances the sensitivity of cancer cells and tumors to EZH2 selective degraders. Collectively, our study sheds new light on a link between two layers of epigenetic regulations at histone modification and RNA editing levels, demonstrates a previously uncharacterized role of EZH2 in RNA editing and mRNA stability independently of its lysine methyltransferase activity, and reveals the significance of EZH2-ADAR1 cascade in governing RNA editing and mRNA stability, which may provide additional perspectives for the advancement of EZH2-targeting cancer therapies.
- 26 March 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessA dual role of EZH2 in regulating A-to-I RNA editing and mRNA stability through ADAR
Adenosine-to-inosine (A-to-I) RNA editing, catalyzed by adenosine deaminases acting on RNA (ADARs), is a widespread modification in metazoans. Cumulative evidence has revealed the altered A-to-I editing profiles in cancers, but the underlying mechanism remains unclear. Here, we discover the well-known histone lysine methyltransferase enhancer of zeste homologue 2 (EZH2) as an unexplored ADAR interactor and editing regulator in prostate cancer (PCa). Through competing with interleukin enhancer binding factor 2 (ILF2) for ADAR1 binding, EZH2 reshapes the substrate selectivity of ADAR1 and thus exhibits a bidirectional role in editing regulation. Moreover, EZH2 depletion induces the translational repression of transportin-1 (TRN1), which further results in the accumulation of cytoplasmic ADAR1p110 isoform to protect many oncogenic transcripts from degradation. Consistently, depletion of ADAR1 dramatically enhances the sensitivity of cancer cells and tumors to EZH2 selective degraders. Collectively, our study sheds new light on a link between two layers of epigenetic regulations at histone modification and RNA editing levels, demonstrates a previously uncharacterized role of EZH2 in RNA editing and mRNA stability independently of its lysine methyltransferase activity, and reveals the significance of EZH2-ADAR1 cascade in governing RNA editing and mRNA stability, which may provide additional perspectives for the advancement of EZH2-targeting cancer therapies.
- 24 March 2026
- Published by Elsevier in Trends in Biochemical Sciences
- Vol. 51 (5) , 418-420
Adenosylhomocysteinase–adenosine complex links m6A and cancer lipid metabolism
- 24 March 2026
- Published by Elsevier in Trends in Biochemical Sciences
- Vol. 51 (5) , 418-420
Adenosylhomocysteinase–adenosine complex links m6A and cancer lipid metabolism
- 4 July 2025
- Published by Springer Nature in Nature Cardiovascular Research
- Vol. 4 (7) , 904-920
O-GlcNAcylation promotes angiogenic transdifferentiation to reverse vascular ischemia
The restoration of the microvasculature is essential to cardiovascular regeneration. Our previous work demonstrated that angiogenic transdifferentiation of fibroblasts into endothelial cells facilitates vascular recovery following limb ischemia and is accompanied by a metabolic shift toward glycolysis. However, a comprehensive characterization of the metabolic alterations that contribute to the transdifferentiation process is still lacking. Here we identify a marked upregulation of uridine diphosphate N-acetylglucosamine (UDP-GlcNAc), the substrate for O-GlcNAcylation, during transdifferentiation. Enhancing this pathway promotes, whereas inhibiting it impairs, the efficiency of transdifferentiation. Mechanistically, we demonstrate that O-GlcNAcylation facilitates chromatin remodeling through modification of HIRA, a histone chaperone responsible for de novo deposition of the noncanonical histone variant H3.3, a process intimately linked to transcriptional activation. These findings are further supported by in vivo lineage tracing and conditional knockout mouse models. Collectively, our study demonstrates that O-GlcNAcylation enhances angiogenic transdifferentiation through a metabolic-and-epigenetic-coupled mechanism, thereby strengthening vascular recovery.
- 4 July 2025
- Published by Springer Nature in Nature Cardiovascular Research
- Vol. 4 (7) , 904-920
O-GlcNAcylation promotes angiogenic transdifferentiation to reverse vascular ischemia
The restoration of the microvasculature is essential to cardiovascular regeneration. Our previous work demonstrated that angiogenic transdifferentiation of fibroblasts into endothelial cells facilitates vascular recovery following limb ischemia and is accompanied by a metabolic shift toward glycolysis. However, a comprehensive characterization of the metabolic alterations that contribute to the transdifferentiation process is still lacking. Here we identify a marked upregulation of uridine diphosphate N-acetylglucosamine (UDP-GlcNAc), the substrate for O-GlcNAcylation, during transdifferentiation. Enhancing this pathway promotes, whereas inhibiting it impairs, the efficiency of transdifferentiation. Mechanistically, we demonstrate that O-GlcNAcylation facilitates chromatin remodeling through modification of HIRA, a histone chaperone responsible for de novo deposition of the noncanonical histone variant H3.3, a process intimately linked to transcriptional activation. These findings are further supported by in vivo lineage tracing and conditional knockout mouse models. Collectively, our study demonstrates that O-GlcNAcylation enhances angiogenic transdifferentiation through a metabolic-and-epigenetic-coupled mechanism, thereby strengthening vascular recovery.
- Open Access
- 29 November 2024
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 10 (48) , eadl2804
EZH2 directly methylates PARP1 and regulates its activity in cancer
DNA repair dysregulation is a key driver of cancer development. Understanding the molecular mechanisms underlying DNA repair dysregulation in cancer cells is crucial for cancer development and therapies. Here, we report that enhancer of zeste homolog 2 (EZH2) directly methylates poly(adenosine diphosphate–ribose) polymerase-1 (PARP-1), an essential enzyme involved in DNA repair, and regulates its activity. Functionally, EZH2-catalyzed methylation represses PARP1 catalytic activity, down-regulates the recruitment of x-ray repair cross-complementing group-1 to DNA lesions and its associated DNA damage repair; on the other hand, it protects the cells from nicotinamide adenine dinucleotide overconsumption upon DNA damage formation. Meanwhile, EZH2-mediated methylation regulates PARP1 transcriptional and oncogenic activity, at least in part, through impairing PARP1-E2F1 interaction and E2F1 transcription factor activity. EZH2 and PARP1 inhibitors synergistically suppress prostate cancer growth. Collectively, our findings uncover an insight of EZH2 functions in fine-tuning PARP1 activity during DNA damage repair and cancer progression, which provides a rationale for combinational targeting EZH2 and PARP1 in cancer.
- 29 November 2024
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 10 (48) , eadl2804
Open AccessEZH2 directly methylates PARP1 and regulates its activity in cancer
DNA repair dysregulation is a key driver of cancer development. Understanding the molecular mechanisms underlying DNA repair dysregulation in cancer cells is crucial for cancer development and therapies. Here, we report that enhancer of zeste homolog 2 (EZH2) directly methylates poly(adenosine diphosphate–ribose) polymerase-1 (PARP-1), an essential enzyme involved in DNA repair, and regulates its activity. Functionally, EZH2-catalyzed methylation represses PARP1 catalytic activity, down-regulates the recruitment of x-ray repair cross-complementing group-1 to DNA lesions and its associated DNA damage repair; on the other hand, it protects the cells from nicotinamide adenine dinucleotide overconsumption upon DNA damage formation. Meanwhile, EZH2-mediated methylation regulates PARP1 transcriptional and oncogenic activity, at least in part, through impairing PARP1-E2F1 interaction and E2F1 transcription factor activity. EZH2 and PARP1 inhibitors synergistically suppress prostate cancer growth. Collectively, our findings uncover an insight of EZH2 functions in fine-tuning PARP1 activity during DNA damage repair and cancer progression, which provides a rationale for combinational targeting EZH2 and PARP1 in cancer.
- Open Access
- 13 October 2023
- Published by Oxford University Press (OUP) in Nucleic Acids Research
- Vol. 51 (21) , 11534-11548
Low RNA stability signifies strong expression regulatability of tumor suppressors
RNA expression of a gene is determined by not only transcriptional regulation, but also post-transcriptional regulation of RNA decay. The precise regulation of RNA stability in the cell plays an important role in normal development. Dysregulation of RNA stability can lead to diseases such as cancer. Here we found tumor suppressor RNAs tended to decay fast in normal cell types when compared with other RNAs. Consistent with a negative effect of m6A modification on RNA stability, we observed preferential deposition of m6A on tumor suppressor RNAs. Moreover, abundant m6A and fast decay of tumor suppressor RNAs both tended to be further enhanced in prostate cancer cells relative to normal prostate epithelial cells. Further, knockdown of m6A methyltransferase METTL3 and reader YTHDF2 in prostate cancer cells both posed stronger effect on tumor suppressor RNAs than on other RNAs. These results indicated a strong post transcriptional expression regulatability mediated by abundant m6A modification on tumor suppressor RNAs.
- 13 October 2023
- Published by Oxford University Press (OUP) in Nucleic Acids Research
- Vol. 51 (21) , 11534-11548
Open AccessLow RNA stability signifies strong expression regulatability of tumor suppressors
RNA expression of a gene is determined by not only transcriptional regulation, but also post-transcriptional regulation of RNA decay. The precise regulation of RNA stability in the cell plays an important role in normal development. Dysregulation of RNA stability can lead to diseases such as cancer. Here we found tumor suppressor RNAs tended to decay fast in normal cell types when compared with other RNAs. Consistent with a negative effect of m6A modification on RNA stability, we observed preferential deposition of m6A on tumor suppressor RNAs. Moreover, abundant m6A and fast decay of tumor suppressor RNAs both tended to be further enhanced in prostate cancer cells relative to normal prostate epithelial cells. Further, knockdown of m6A methyltransferase METTL3 and reader YTHDF2 in prostate cancer cells both posed stronger effect on tumor suppressor RNAs than on other RNAs. These results indicated a strong post transcriptional expression regulatability mediated by abundant m6A modification on tumor suppressor RNAs.
- Open Access
- 18 May 2023
- Published by Springer Nature in Nature Communications
- Vol. 14 (1) , 1
Publisher Correction: Epigenetic landscape reveals MECOM as an endothelial lineage regulator
- 18 May 2023
- Published by Springer Nature in Nature Communications
- Vol. 14 (1) , 1
Open AccessPublisher Correction: Epigenetic landscape reveals MECOM as an endothelial lineage regulator
- Open Access
- 25 April 2023
- Published by Springer Nature in Nature Communications
- Vol. 14 (1) , 1-17
Epigenetic landscape reveals MECOM as an endothelial lineage regulator
A comprehensive understanding of endothelial cell lineage specification will advance cardiovascular regenerative medicine. Recent studies found that unique epigenetic signatures preferentially regulate cell identity genes. We thus systematically investigate the epigenetic landscape of endothelial cell lineage and identify MECOM to be the leading candidate as an endothelial cell lineage regulator. Single-cell RNA-Seq analysis verifies that MECOM-positive cells are exclusively enriched in the cell cluster of bona fide endothelial cells derived from induced pluripotent stem cells. Our experiments demonstrate that MECOM depletion impairs human endothelial cell differentiation, functions, and Zebrafish angiogenesis. Through integrative analysis of Hi-C, DNase-Seq, ChIP-Seq, and RNA-Seq data, we find MECOM binds enhancers that form chromatin loops to regulate endothelial cell identity genes. Further, we identify and verify the VEGF signaling pathway to be a key target of MECOM. Our work provides important insights into epigenetic regulation of cell identity and uncovered MECOM as an endothelial cell lineage regulator.
- 25 April 2023
- Published by Springer Nature in Nature Communications
- Vol. 14 (1) , 1-17
Open AccessEpigenetic landscape reveals MECOM as an endothelial lineage regulator
A comprehensive understanding of endothelial cell lineage specification will advance cardiovascular regenerative medicine. Recent studies found that unique epigenetic signatures preferentially regulate cell identity genes. We thus systematically investigate the epigenetic landscape of endothelial cell lineage and identify MECOM to be the leading candidate as an endothelial cell lineage regulator. Single-cell RNA-Seq analysis verifies that MECOM-positive cells are exclusively enriched in the cell cluster of bona fide endothelial cells derived from induced pluripotent stem cells. Our experiments demonstrate that MECOM depletion impairs human endothelial cell differentiation, functions, and Zebrafish angiogenesis. Through integrative analysis of Hi-C, DNase-Seq, ChIP-Seq, and RNA-Seq data, we find MECOM binds enhancers that form chromatin loops to regulate endothelial cell identity genes. Further, we identify and verify the VEGF signaling pathway to be a key target of MECOM. Our work provides important insights into epigenetic regulation of cell identity and uncovered MECOM as an endothelial cell lineage regulator.
- Open Access
- 5 March 2021
- Published by Oxford University Press (OUP) in Genomics, Proteomics & Bioinformatics
- Vol. 19 (1) , 140-153
MACMIC Reveals a Dual Role of CTCF in Epigenetic Regulation of Cell Identity Genes
Numerous studies of relationship between epigenomic features have focused on their strong correlation across the genome, likely because such relationship can be easily identified by many established methods for correlation analysis. However, two features with little correlation may still colocalize at many genomic sites to implement important functions. There is no bioinformatic tool for researchers to specifically identify such feature pairs. Here, we develop a method to identify feature pairs in which two features have maximal colocalization minimal correlation (MACMIC) across the genome. By MACMIC analysis of 3306 feature pairs in 16 human cell types, we reveal a dual role of CCCTC-binding factor (CTCF) in epigenetic regulation of cell identity genes. Although super-enhancers are associated with activation of target genes, only a subset of super-enhancers colocalized with CTCF regulate cell identity genes. At super-enhancers colocalized with CTCF, CTCF is required for the active marker H3K27ac in cell types requiring the activation, and also required for the repressive marker H3K27me3 in other cell types requiring repression. Our work demonstrates the biological utility of the MACMIC analysis and reveals a key role for CTCF in epigenetic regulation of cell identity. The code for MACMIC is available at https://github.com/bxia888/MACMIC.
- 5 March 2021
- Published by Oxford University Press (OUP) in Genomics, Proteomics & Bioinformatics
- Vol. 19 (1) , 140-153
Open AccessMACMIC Reveals a Dual Role of CTCF in Epigenetic Regulation of Cell Identity Genes
Numerous studies of relationship between epigenomic features have focused on their strong correlation across the genome, likely because such relationship can be easily identified by many established methods for correlation analysis. However, two features with little correlation may still colocalize at many genomic sites to implement important functions. There is no bioinformatic tool for researchers to specifically identify such feature pairs. Here, we develop a method to identify feature pairs in which two features have maximal colocalization minimal correlation (MACMIC) across the genome. By MACMIC analysis of 3306 feature pairs in 16 human cell types, we reveal a dual role of CCCTC-binding factor (CTCF) in epigenetic regulation of cell identity genes. Although super-enhancers are associated with activation of target genes, only a subset of super-enhancers colocalized with CTCF regulate cell identity genes. At super-enhancers colocalized with CTCF, CTCF is required for the active marker H3K27ac in cell types requiring the activation, and also required for the repressive marker H3K27me3 in other cell types requiring repression. Our work demonstrates the biological utility of the MACMIC analysis and reveals a key role for CTCF in epigenetic regulation of cell identity. The code for MACMIC is available at https://github.com/bxia888/MACMIC.